Inari Medical price target raised at Piper after agreeing to be acquired

Piper Sandler raised the firm’s price target on Inari Medical (NARI) to $80 from $52 and keeps a Neutral rating on the shares after the company agreed to be acquired by Stryker (SYK) for an enterprise deal value of $4.8B. The firm thinks the combination makes sense and provides Stryker with a nice complement to the company’s neuro franchise, the analyst tells investors in a research note.